Prevalence of anti-SARS-CoV-2 antibodies in Poznań, Poland, after the first wave of the COVID-19 pandemic

Dagny Lorent,* Rafał Nowak,* Carolina Roxo, Elżbieta Lenartowicz, Aleksandra Makarewicz, Bartosz Zaremba, Szymon Nowak, Łukasz Kuszel, Jerzy Stefaniak, Ryszard Kierzek, Pawel Zmora

Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland (D. Lorent, R. Nowak, C. Roxo, E. Lenartowicz, A. Makarewicz, B. Zaremba, R. Kierzek, P. Zmora)

Department and Clinic of Tropical and Parasitic Diseases, Poznan University of Medical Sciences, Poznan, Poland (S. Nowak, J. Stefaniak)

Department of Medical Genetics, Poznan University of Medical Sciences, Poznan, Poland (Ł. Kuszel)

Abstract

A serosurvey of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was performed between July and September 2020. Within this study, we found that 0.93% of the Poznań metropolitan area's population had been exposed to SARS-CoV-2 after the first wave of coronavirus disease 2019 (COVID-19).

After the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in December 2019 in Wuhan, China, the World Health Organization reported almost 81.5 million confirmed cases of SARS-CoV-2 infections and over 1.8 million deaths related to the virus worldwide in 2020 (1). In 2020, Poland was hit by “two waves” of the pandemic, with 1.3 million confirmed SARS-CoV-2 infections and 28.5 thousand deaths caused by the novel coronavirus (2). Due to the political decisions to test only symptomatic patients (2), unspecific symptoms of COVID-19 (3), and asymptomatic SARS-CoV-2 infections (4), those numbers may be underestimated.

The aims of the present sero-epidemiological study were to estimate the prevalence of SARS-CoV-2 antibodies in the population of the Poznań metropolitan area (Poland) after the first wave of the COVID-19 pandemic, to find the risk factors associated with COVID-19 and to compare the immunoassays in detecting anti-SARS-CoV-2 antibodies.

The Study

We randomly selected and invited 1500 adult (over 18 years old) study participants from approximately 15,000 volunteers living in the Poznań metropolitan area, Poland, who answered the online epidemiological survey. Demographic data, including age, gender and occupation of each participant, were collected. Additionally, we asked volunteers about their current health status, potential flu-like symptoms in the last nine months and behavior during the COVID-19 pandemic, namely compliance with epidemiological recommendations. To estimate the severity of an individual’s flu-like symptoms, we developed a scoring system based on subjects’ self-assessment answers. If the patient did not show any symptoms, a value of 0 was assigned. Each symptom, such as fever, cough, runny nose, fatigue, muscle and joint pain, sore throat, headache,

diarrhea and loss of smell or taste, was rated as 1, and hospitalization due to the flu-like symptoms was rated as 5. Additionally, the study participants were asked to compare flu-like symptoms in the last nine months before the serological test to flu-like symptoms in the previous years. Symptoms of flu-like illness in the last nine months milder than in the past were graded as 0, the same as 3 and more severe as 5. Based on the total sum of values of individual responses, study participants were divided into four groups: “symptomatic” (0 points), “mild” (1–5 points), “moderate” (6–14 points) or “severe” (15–24 points). A similar classification approach was implemented to assess individuals’ compliance with epidemiological recommendations. If the study participant did not follow any recommendations, a value of 0 was assigned. Each of the preventive measures, such as face mask use, disinfection and social distance, remote work, avoiding contact with other people, and avoiding the use of public transport, was rated as 1. Depending on the total sum of values of individual responses, study participants were divided into three groups: “non-compliant” (0 points), “at some point” (1–2 points) and “in general” (3–4 points) compliant with epidemiological recommendations.

The blood samples were collected from individuals between July and September 2020 at the Wielkopolskie Centrum Medycyny Podróży, Poznan, and transferred to the IBCH PAS for further analysis. In case of positive results for the presence of anti-SARS-CoV-2 IgA or borderline results for the anti-SARS-CoV-2 IgG, the study participants were asked to come again within 2–3 weeks and an ELISA analysis was repeated. For five study participants with anti-SARS-CoV-2 IgG-positive results, we did the follow-up analysis at 10 weeks after the first test.

The presence of IgA and IgG antibodies against SARS-CoV-2 was determined using anti-SARS-CoV-2 IgA ELISA (EuroImmun) or anti-SARS-CoV-2 IgG ELISA (EuroImmun) assays, respectively. The chosen immunoassays recognized specific anti-SARS-CoV-2 antibodies

against the spike (S) protein. All anti-SARS-CoV-2 IgG positive-samples were confirmed with quantitative anti-SARS-CoV-2 IgG immunoblot (Polycheck), which uses the S protein and phosphorylated nucleocapsid protein (PNC) as antigens.

The categorical variables were presented as counts and percentages, and the seroprevalence estimates were presented together with 95%CI. The 95%CI of the seroprevalence was calculated using the hybrid Wilson/Brown method. All statistical analyses were performed with the GraphPad Prism 9 software.

The study was approved by the Bioethics Committee at the Poznan University of Medical Sciences, Poznan, Poland (Resolution No. 470/20 from 17th June 2019). In addition, written informed consent was obtained from each study participant.

In total, 25 of 1500 (1.67%) collected samples were found to be positive for anti-SARS-CoV-2 IgG antibodies (Table 1). Simultaneously, 60 of 1500 (4.0%) collected samples were found to be positive for anti-SARS-CoV-2 IgA antibodies, but in any of those cases, we did not observe IgA to IgG seroconversion (data not shown). The presence of anti-SARS-CoV-2 IgG antibodies was not confirmed with immunoblot in 11 of 25 samples, mostly among study participants between 18 and 33 years old, as well as among volunteers with autoimmunological and respiratory system chronic diseases (Table 1). The highest anti-SARS-CoV-2 IgG seroprevalence was found among study participants over 65 years old, working in positions related to constant contact with people (e.g., physicians, nurses, shop assistants, civil servants), and travelling abroad (Table 1). Others were individuals who did not follow epidemiological recommendations, persons who had direct contact with SARS-CoV-2, and study participants with confirmed SARS-CoV-2 infection (Table 2). Additionally, we found that among the tested

study participants, 35% of SARS-CoV-2 infections followed an asymptomatic course (Table 1). Finally, we observed different levels of anti-SARS-CoV-2 IgG antibodies among the study participants (Figure 1A), which was not altered significantly within 10 weeks (Figure 1B).

Discussion

To our knowledge, this is the first investigation of SARS-CoV-2 seroprevalence in the general population in Poland. For many months, the reported novel coronavirus infection cases and COVID-19-related mortality in Poland were among the lowest in Europe. For example, in October 2020, there were 91,514 confirmed SARS-CoV-2 cases and 2,513 COVID-19-related deaths in total, but at the same time, in Spain there were 778,607 confirmed infections and 31,791 deaths in total (1, 5). Our study demonstrates low seroprevalence of SARS-CoV-2 in Poznan (0.93%), one of the biggest cities in Poland, which, in our opinion, may represent the situation in the whole country. In comparison, at similar time points, the anti-SARS-CoV-2 seroprevalence in Madrid, Spain, was equal to 13.6% (6); in Geneva, Switzerland, it was 10.8% (7), and in Tehran, Iran, it was 16.3% (8).

This low percentage of individuals with anti-SARS-CoV-2 antibodies in Poznan may result from early implementation of public health measures, such as the closing of primary schools and the so-called deep lockdown in March and April 2020. On the other hand, this situation ensured that as of September 2020, the Polish population remained largely immunologically naïve to the virus, which explains the dramatic numbers of cases during the second wave of the pandemic (2). However, it should be noted that based on the seroprevalence of 0.93%, it is estimated that approximately 4-fold more infections occurred than were reported by Polish Ministry of Health. These differences may occur among others from the asymptomatic

SARS-CoV-2 infections, not included in the SARS-CoV-2 Polish testing strategy, which according to our study can reach 35% of all cases, while other suggest that even 66-80% of seropositive cases were associated with asymptomatic infection (9, 10). Moreover, it should be noted that our study has several limitations, i.e., sensitivity and specificity of serological tests, which can bias the results.

In conclusion, our findings confirm the low SARS-CoV-2 incidence in Poland and the effectiveness of early counter-measures.

Acknowledgments

This work was funded by the National Science Center (Poland), grant UMO-2020/01/0/NZ6/00152. The authors would like to thank Aleksandra Jarmołowicz and Julia Jabłońska from the Institute of Bioorganic Chemistry, Polish Academy of Sciences, for their help with volunteers' phone contact. In addition, the authors are grateful to Katarzyna Wysocka and Danuta Kuczmińska from Wielkopolskie Centrum Medycyny Podróży for their assistance with blood sample collection.

Author Bio

Dagny Lorent is a PhD student in the Institute of Bioorganic Chemistry Polish Academy of Sciences, Poznań, Poland. Her research work focuses on molecular biology of microorganisms and structural biology. Rafał Nowak is a PhD student at the Institute of

Bioorganic Chemistry Polish Academy of Sciences, Poznań, Poland. His research interests include emerging viruses, virus-host interactions and structural biology.

Footnotes

[*] These authors contributed equally to this article.

References

1. World Health Organization. Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
2. Polish Ministry of Health. Coronavirus: information and recommendations. https://www.gov.pl/web/koronawirus
3. Baj J, Karakuła-Juchnowicz H, Teresinski G, Buszewicz G, Ciesielka M, Sitarz E, et al. COVID-19: Specific and non-specific clinical manifestations and symptoms: the current state of knowledge. J Clin Med. 2020;9:1753
4. Nikolai LA, Meyer CG, Kremsner PG, Velavan TP. Asymptomatic SARS Coronavirus 2 infection: Invisible yet invincible. Int J Infect Dis. 2020;100:112-116
5. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20:533-534

6. Pollan M, Perez-Gomez B, Pastor-Barriuso R, Oteo J, Hernan MA, Perez-Olmeda M, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020; 396:535-44
7. Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020;396:313-9
8. Poutschi H, Darvishian M, Mohammadi Z, Shayanrad A, Delavari A, Bahadorimonfared A, et al. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study. Lancet Infect Dis. 2021;24:473-481
9. Rogawski-McQuade ET, Guertin KA, Becker L, Operario D, Gratz J, Guan D, et al. Assesment of seroprevalence of SARS-CoV-2 and risk factors associated with COVID-19 infection among outpatients in Virginia. JAMA Network Open. 2021;4:e2035234
10. Meyerowitz EA, Richterman A, Bogoch II, Low N, Cevik M. Towards and accurate and systematic characterisation of persistently asymptomatic infection with SARS-CoV-2. Lancet Infect Dis. https://doi.org/10.1016/S1473-3099(20)30837-9

Address for correspondence: Pawel Zmora, PhD, Institute of Bioorganic Chemistry Polish Academy of Sciences, ul. Noskowskiego 12/14, 61-704 Poznan, Poland; email: pzmora@ibch.poznan.pl

Table 1. Prevalence of anti-SARS-CoV-2 IgG antibodies in Poznań metropolitan area.

Category	Participants	ELISA		Western blot	
		Positive results	Seroprevalence (95%CI)	Positive results	Seroprevalence (95%CI)
Overall					
	1500	25	1.67% (1.13-2.45)	14	0.93% (0.56-1.56)
Gender					
Female	896	14	1.56% (0.93-2.60)	8	0.89% (0.45-1.75)
Male	604	11	1.82% (1.02-3.23)	6	0.99% (0.46-2.15)
Age					
18-33	623	10	1.61% (0.87-2.92)	5	0.80% (0.34-1.87)
34-49	606	11	1.82% (1.02-3.22)	7	1.16% (0.56-2.37)
50-65	194	2	1.03% (0.18-3.68)	0	0.00% (0.00-1.94)
65+	77	2	2.60% (0.46-8.99)	2	2.60% (0.46-8.99)
Chronic diseases (CD)					
None	964	16	1.66% (1.02-2.70)	11	1.14% (0.64-2.03)
Circulatory system CD (i.e., hypertension)	185	1	0.54% (0.03-3.00)	1	0.54% (0.03-3.00)
Respiratory system CD (i.e., asthma)	78	3	3.85% (1.05-10.71)	0	0.00% (0.00-4.69)

Infectious CD (i.e., HIV/AIDS)	8	0	0.00% (0.00-32.44)	0	0.00% (0.00-32.44)
Chronic kidney disease	1	0	0.00% (0.00-94.87)	0	0.00% (0.00-94.87)
Digestive track CD (i.e., Crohn disease)	23	0	0.00% (0.00-14.31)	0	0.00% (0.00-14.31)
Autoimmunological diseases (i.e., rheumatoid arthritis)	170	4	2.35% (0.90-5.76)	1	0.59% (0.03-3.26)
Neoplasmatic diseases	5	0	0.00% (0.00-43.45)	0	0.00% (0.00-43.45)
Metabolic diseases (i.e., diabetes)	50	1	2.00% (0.10-10.50)	1	2.00% (0.10-10.50)
Mental disorders (i.e., depression)	29	0	0.00% (0.00-11.70)	0	0.00% (0.00-11.70)
Severity of flu-like illness in the last 9 month before serological tests					
No symptoms	260	8	3.08% (1.57-5.95)	5	1.92% (0.82-4.42)
Mild symptoms	454	5	1.10% (0.42-2.30)	4	0.88% (0.34-2.24)
Moderate symptoms	720	12	1.67% (0.96-2.89)	5	0.69% (0.30-1.62)
Severe symptoms	66	0	0.00% (0.00-5.50)	0	0,00% (0.00-5.50)
Test for the presence of SARS-CoV2					
Positive	7	3	42.86% (15.82-74.95)	3	42.86% (15.82-74.95)
Negative	349	8	2.29% (1.17-4.46)	6	1.72% (0.79-3.70)

No test	1144	14	1.22% (0.73-2.04)	5	0.44% (0.19-1.02)

Table 2. Anti-SARS-CoV-2 IgG seroprevalence and COVID19 risk factors.

Category	Participants	ELISA		Western blot	
		Positive results	Seroprevalence (95%CI)	Positive results	Seroprevalence (95%CI)
Occupation related to constant contact with people (i.e., physicians, nurses, shop assistants, civil servants)					
Yes	749	11	1.47% (0.82-2.61)	9	1.20% (0.63-2.27)
No	751	14	1.86% (1.11-3.11)	5	0.67% (0.29-1.55)
Travelling abroad in the last 9 months					
Yes	547	16	2.93% (1.81-4.70)	8	1.46% (0.74-2.86)
No	953	9	0.94% (0.50-1.78)	6	0.63% (0.29-1.37)
Compliance with epidemiological recommendations (i.e. remote work, wearing a mask covering nose and mouth, avoiding contact with other people, avoiding the use of public transport)					
No	46	1	2.17% (0.11-11.33)	1	2.17% (0.11-11.34)
At some point	405	6	1.48% (0.68-3.19)	4	0.99% (0.39-2.51)
Yes, in general	1049	18	1.72% (1.09-2.70)	9	0.86% (0.45-1.62)
Contact with SARS-CoV2 infected person					
Yes	40	2	5.00% (0.85-15.79)	2	5.00% (0.89-16.50)
No	375	7	1.87% (0.91-3.80)	5	1.33% (0.57-3.08)

I don’t know	1085	16	1.47% (0.91-2.38)	7	0.65% (0.31-1.33)

Figure 1. Anti-SARS-CoV-2 antibodies levels among volunteers. (A) The total levels of anti-SARS-CoV-2 phosphorylated nucleoprotein (PNC) and anti-SARS-CoV-2 spike (S) antibodies among study participants. (B) The changes in the anti-SARS-CoV-2 PNC (left) and anti-SARS-CoV-2 S (right) antibodies levels within 10 weeks in five study participants.

Figure 1

A)


100
10
1
0.1
0.01
IgG (kU/l)
PNC
S

B)


10
1
0.1
Anti-SARS-CoV-2 PNC IgG (kU/l)
July
September


100
10
1
0.1
Anti-SARS-CoV-2 S IgG (kU/l)
July
September